All Institutions
Emory University
Atlanta, Georgia, US
Summarized by Halo AI
Private research university in Atlanta with an integrated health system, hospital-based innovation hub, clinical trials network, tech transfer office, and proximity to the CDC and major corporate HQs.
Emory University is a comprehensive private research university in Atlanta, anchored by a major academic health center and a mid-sized, research-active faculty. Integration with its academic health system provides direct access to patients, clinicians, and real-world data, enabling rapid clinical translation and large, multisite trials. A hospital-embedded innovation hub and proximity to the CDC and Atlanta’s corporate ecosystem create frequent pathways for co-development, testing, and deployment with industry partners; a long-standing partnership with a neighboring engineering powerhouse broadens prototyping and scale-up options. Research is supported by competitive federal funding, including the National Institutes of Health and the National Science Foundation. A dedicated technology transfer office supports IP strategy, licensing, startup formation, and streamlined industry agreements.Top industry applications
Halo’s AI pipeline combines publication data and faculty input to determine the industry applications with greatest concentration of publishing faculty. It then surfaces those with the strongest industry collaboration evidence.
Medicine
Medical diagnostics
Emory researchers are developing AI-driven diagnostic platforms that interpret radiology and ocular images, predict cancer spread from routine scans, and identify malignant blood cancers with deep-learning classifiers. They are also translating rapid infectious disease tests and wearable physiological sensors into emergency and outpatient workflows for real-time cardiac and neurological monitoring. These technologies target faster clinical decision-making, reduced diagnostic disparities, and scalable commercial deployment in precision medicine.Relevant Innovators
Nicholas T. Seyfried
Unclaimed
Medical diagnosticsNeurology & neurological disease
Medical diagnosticsNeurology & neurological diseaseWilbur A. Lam
Unclaimed
Consumer at-home diagnosticsDigital health applicationsMedical diagnostics
Consumer at-home diagnosticsDigital health applicationsMedical diagnosticsJohn D. Roback
Unclaimed
Infectious disease & antimicrobialsMedical diagnostics
Infectious disease & antimicrobialsMedical diagnosticsMedicine
Oncology & cancer therapeutics
Emory researchers develop next-generation immunotherapies and targeted drugs to overcome resistance in lung, breast, prostate, and blood cancers. They combine AI-driven diagnostics, spatial transcriptomics, and ultra-high-throughput screening to identify predictive biomarkers and advance precision treatments including enhanced CAR-T cells and antibody-drug conjugates. By translating tumor biology into clinically actionable targets, the work supports commercial oncology pipelines and addresses critical gaps across solid and hematologic malignancies.Medicine
Infectious disease & antimicrobials
Emory researchers are advancing long-acting HIV prevention, AI-driven sepsis prediction, and rapid point-of-care diagnostics for tuberculosis and sexually transmitted infections to close critical care gaps. They are also translating novel ESKAPE-targeting antibiotics, phage-antibiotic combination therapies, and real-time disease surveillance into scalable solutions that address antimicrobial resistance and emerging outbreaks.Relevant Innovators
WW
William Wuest
Principal Investigator
Infectious disease & antimicrobialsPharmaceuticals and drug deliverySurface care & disinfection
Infectious disease & antimicrobialsPharmaceuticals and drug deliverySurface care & disinfectionCarlos Del Rı́o
Unclaimed
Infectious disease & antimicrobials
Infectious disease & antimicrobialsDavid S. Weiss
Unclaimed
Infectious disease & antimicrobials
Infectious disease & antimicrobialsMedicine
Pharmaceuticals and drug delivery
Emory teams engineer mRNA-LNP, liposomal, and extracellular vesicle platforms for targeted respiratory, spinal, and cancer drug delivery. They pair these systems with novel photosensitizers, radiopharmaceuticals, and AI-driven small-molecule discovery to attack resistant glioblastoma, breast cancer, and infectious disease. The work generates a robust pipeline of translational candidates with clear biopharma commercialization pathways.Relevant Innovators
EO
Edikan Ogunnaike
Principal Investigator
Oncology & cancer therapeuticsPharmaceuticals and drug delivery
Oncology & cancer therapeuticsPharmaceuticals and drug deliveryRaymond F. Schinazi
Unclaimed
Medical diagnosticsPharmaceuticals and drug delivery
Medical diagnosticsPharmaceuticals and drug deliveryKhalid Salaita
Unclaimed
Medical diagnosticsPharmaceuticals and drug delivery
Medical diagnosticsPharmaceuticals and drug deliveryMedicine
Neurology & neurological disease
Emory University is building a pipeline of commercially viable neurology solutions, from AI algorithms that detect dementia and automate critical-care EEG to wearable patches that monitor opioid withdrawal and plasma tests that predict ALS onset. Researchers are also advancing invasive and noninvasive neuromodulation—including focused ultrasound and speech neuroprostheses—to treat Parkinson’s, essential tremor, and drug-resistant epilepsy. Together, these platforms address urgent industry demand for early diagnostics, remote neurological monitoring, and minimally invasive therapies that improve outcomes in neurodegenerative, cerebrovascular, and neuropsychiatric diseases.Relevant Innovators
Allan I. Levey
Unclaimed
Medical diagnosticsNeurology & neurological disease
Medical diagnosticsNeurology & neurological diseaseStewart A. Factor
Unclaimed
Medical diagnosticsNeurology & neurological disease
Medical diagnosticsNeurology & neurological diseaseJonathan D. Glass
Unclaimed
Neurology & neurological diseasePharmaceuticals and drug delivery
Neurology & neurological diseasePharmaceuticals and drug deliveryMedicine
Cardiovascular health
Emory researchers leverage AI-powered radiomics and opportunistic imaging—reading cardiac CT, echocardiograms, and even mammograms—to detect heart failure, coronary disease, and vascular aging earlier and more equitably. Their clinical trials and real-world evidence studies on transcatheter valves, leadless pacemakers, and mechanical circulatory support are advancing minimally invasive device solutions that shorten hospital stays and serve expanding patient populations. Backing these innovations, teams are commercializing wearable sensors, automated ECG analysis, and digital twin platforms that enable remote precision cardiology and reduce systemic costs.Relevant Innovators
AS
Amit Shah
Principal Investigator
Cardiovascular healthMedical diagnosticsMedical imaging
Cardiovascular healthMedical diagnosticsMedical imagingArshed A. Quyyumi
Unclaimed
Cardiovascular healthMedical diagnostics
Cardiovascular healthMedical diagnosticsRobert A. Guyton
Unclaimed
Cardiovascular healthSurgical technologies
Cardiovascular healthSurgical technologiesMedicine
Immunology & immune-mediated disease
Emory scientists are advancing next-generation immunotherapies—from optimized CAR-T cells and tumor vaccines to novel biologics for lupus and transplant rejection. Their research decodes immune dysregulation in cancer, autoimmunity, and HIV to identify druggable targets that restore tolerance or amplify antitumor responses. These efforts translate fundamental immunology into precision medicines with clear pathways to clinical development and industry partnership.Relevant Innovators
Arash Grakoui
Unclaimed
Immunology & immune-mediated diseaseInfectious disease & antimicrobialsVaccine development
Immunology & immune-mediated diseaseInfectious disease & antimicrobialsVaccine developmentRafick‐pierre Sékaly
Unclaimed
Immunology & immune-mediated diseaseInfectious disease & antimicrobialsMedical diagnosticsVaccine development
Immunology & immune-mediated diseaseInfectious disease & antimicrobialsMedical diagnosticsVaccine developmentRafi Ahmed
Unclaimed
Immunology & immune-mediated diseaseOncology & cancer therapeutics
Immunology & immune-mediated diseaseOncology & cancer therapeuticsMedicine
Medical imaging
Emory researchers are harnessing AI and advanced quantitative imaging across radiology, pathology, and ophthalmology to detect cancers, predict cardiovascular risk, and streamline diagnostic workflows with greater speed and accuracy. Their innovations include deep learning models for CT, MRI, and PET analysis, radiomic biomarkers that forecast patient outcomes, and point-of-care slide-free histology technologies that reduce turnaround times and costs. These solutions directly address industry needs for scalable diagnostic automation, precision medicine support, and improved clinical decision-making in diverse healthcare settings.Relevant Innovators
Xiaofeng Yang
Unclaimed
Medical imagingOncology & cancer therapeutics
Medical imagingOncology & cancer therapeuticsElizabeth A. Krupinski
Unclaimed
Medical diagnosticsMedical imaging
Medical diagnosticsMedical imagingDavid M. Schuster
Unclaimed
Medical diagnosticsMedical imagingOncology & cancer therapeutics
Medical diagnosticsMedical imagingOncology & cancer therapeuticsLast updated by Halo AI Aug 6, 2026. Please verify key information.
OpenAlex
OpenAlexAre you an admin at this institution? Claim this page and invite your faculty.
Claim your free pageTop industry applications
Medical diagnosticsOncology & cancer therapeuticsInfectious disease & antimicrobialsPharmaceuticals and drug deliveryNeurology & neurological diseaseCardiovascular healthImmunology & immune-mediated diseaseMedical imaging
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.